Study of the Pan-ERBB Inhibitor Neratinib Given in Combination With Everolimus, Palbociclib or Trametinib in Advanced Cancer Subjects With EGFR Mutation/Amplification, HER2 Mutation/Amplification, HER3/4 Mutation or KRAS Mutation
about
Study of the Pan-ERBB Inhibitor Neratinib Given in Combination With Everolimus, Palbociclib or Trametinib in Advanced Cancer Subjects With EGFR Mutation/Amplification, HER2 Mutation/Amplification, HER3/4 Mutation or KRAS Mutation
description
clinical trial
@en
klinisch onderzoek
@nl
name
Study of the Pan-ERBB Inhibito ...... R3/4 Mutation or KRAS Mutation
@en
type
label
Study of the Pan-ERBB Inhibito ...... R3/4 Mutation or KRAS Mutation
@en
prefLabel
Study of the Pan-ERBB Inhibito ...... R3/4 Mutation or KRAS Mutation
@en
P4844
P1476
Phase I Study of the Pan-ERBB ...... R3/4 Mutation or KRAS Mutation
@en
P3098
NCT03065387
P580
2017-10-31T00:00:00Z
P582
2022-10-01T00:00:00Z